Serum PIVKA – II Level at Chughtai Lab

Serum PIVKA – II Level at Chughtai Lab

The Serum PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II) level test is an advanced, highly specific diagnostic laboratory investigation primarily utilized as a tumor marker for Hepatocellular Carcinoma (HCC). Also known as Des-gamma-carboxy prothrombin (DCP), PIVKA-II is an abnormal, non-functional form of prothrombin, a crucial blood-clotting protein synthesized by the liver. In a healthy physiological state, the synthesis of prothrombin requires Vitamin K to catalyze the gamma-carboxylation of specific glutamic acid residues. When Vitamin K is deficient, or when malignant transformation occurs within hepatocytes—such as in hepatocellular carcinoma—this carboxylation process is severely impaired. Consequently, the liver releases uncarboxylated prothrombin (PIVKA-II) into the systemic circulation. Measuring these levels provides critical clinical insights into hepatic malignancies and metabolic abnormalities.

At Chughtai Lab, Pakistan’s leading diagnostic network, the Serum PIVKA-II level test is performed using state-of-the-art automated immunoassay technology. This ensures exceptional analytical sensitivity and specificity, allowing for the detection of minute concentrations of this biomarker. The clinical importance of PIVKA-II lies in its ability to serve as an early indicator of hepatocellular carcinoma, often rising before structural abnormalities become visible on standard imaging modalities like ultrasound, CT scans, or MRI. Furthermore, when combined with Alpha-Fetoprotein (AFP), another widely recognized liver tumor marker, PIVKA-II significantly enhances the diagnostic accuracy, sensitivity, and specificity for early-stage HCC detection. This synergistic approach allows hepatologists, oncologists, and gastroenterologists to identify high-risk patients, monitor chronic liver disease progression, and evaluate the therapeutic efficacy of interventions such as surgical resection, liver transplantation, or transarterial chemoembolization (TACE).

Clinical Procedure for PIVKA-II Test: What to Expect

Patient Preparation

Appropriate patient preparation is essential to ensure the clinical validity and accuracy of the Serum PIVKA-II level test. Patients are advised to adhere to the following guidelines prior to sample collection:

• Medication Disclosure: It is imperative to inform the healthcare provider and the laboratory staff at Chughtai Lab of all ongoing medications, particularly oral anticoagulants such as Warfarin or other Vitamin K antagonists. These medications deliberately interfere with Vitamin K metabolism and will cause a physiological elevation in PIVKA-II levels, which must be clinically correlated.
• Dietary Supplements: Patients should disclose the use of any Vitamin K supplements or multivitamins containing Vitamin K, as these can artificially lower PIVKA-II levels and potentially mask underlying pathology.
• Fasting Requirements: Routine fasting is generally not mandatory for the Serum PIVKA-II test. However, patients should follow any specific dietary instructions provided by their referring physician, especially if other concurrent blood tests (such as fasting lipid profiles or blood glucose) are scheduled.
• Alcohol Consumption: Patients are advised to avoid alcohol consumption for at least 24 hours prior to the test, as alcohol can acutely alter liver enzyme activity and metabolic processes.

During the Procedure

The Serum PIVKA-II level test is a straightforward outpatient blood investigation. The procedure is conducted by highly trained phlebotomists at Chughtai Lab and involves the following steps:

• Patient Identification and Verification: The phlebotomist will verify the patient’s identity using standard protocols and review the test requisition form to confirm any specific clinical indications or medication history.
• Aseptic Technique: The patient will be seated comfortably. The phlebotomist will select a suitable vein, typically the median cubital vein in the antecubital fossa of the arm. The skin over the venipuncture site is thoroughly cleansed with an antiseptic swab (70% isopropyl alcohol) and allowed to air dry.
• Venipuncture and Sample Collection: A sterile, single-use needle is inserted into the vein, and a specific volume of blood (usually 3 to 5 mL) is drawn into a serum separator tube (SST) or a plain red-top tube. A tourniquet may be applied briefly to facilitate vein visualization but is released promptly to prevent hemoconcentration.
• Post-Puncture Care: Once the sample is collected, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball or gauze to prevent hematoma formation. A small adhesive bandage is applied.
• Safety and Comfort: The entire venipuncture process takes less than five minutes. Patients may experience a mild, transient pinching sensation during needle insertion. The risk of complications is extremely low, limited to minor bruising or localized soreness at the injection site.

When is a Serum PIVKA – II Level Test Performed?

Surveillance of Hepatocellular Carcinoma (HCC)

Physicians frequently request the Serum PIVKA-II level test for the surveillance of hepatocellular carcinoma in high-risk patient populations. This includes individuals diagnosed with liver cirrhosis, chronic Hepatitis B virus (HBV) infection, or chronic Hepatitis C virus (HCV) infection. Because early-stage HCC is often asymptomatic, regular surveillance using PIVKA-II, alongside abdominal ultrasonography, assists clinicians in detecting malignant transformations at a highly treatable stage, significantly improving patient survival rates.

Monitoring Chronic Liver Disease and Cirrhosis

In patients suffering from long-standing chronic liver diseases, such as non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), or autoimmune hepatitis, the liver parenchyma undergoes progressive fibrotic changes leading to cirrhosis. Clinicians utilize the PIVKA-II test to monitor these patients for signs of decompensation or neoplastic development, as cirrhotic patients possess a significantly elevated risk of developing primary liver malignancies.

Evaluating Vitamin K Deficiency

Since PIVKA-II is produced in the absence of adequate Vitamin K, this test serves as a highly sensitive biomarker for subclinical or clinical Vitamin K deficiency. It is particularly useful in evaluating patients with malabsorption syndromes (such as Celiac disease, Crohn’s disease, or chronic pancreatitis), prolonged obstructive jaundice (which impairs fat-soluble vitamin absorption), or those on long-term broad-spectrum antibiotic therapy that depletes gut microbiota responsible for Vitamin K synthesis.

Assessing Response to HCC Therapy

For patients undergoing active treatment for hepatocellular carcinoma, the Serum PIVKA-II level test is an invaluable tool for oncologists to assess therapeutic response. A significant post-treatment decline in PIVKA-II levels indicates successful tumor eradication or reduction. Conversely, persistent elevation or a subsequent rise in PIVKA-II levels during follow-up strongly suggests tumor recurrence, incomplete resection, or resistance to systemic therapies like tyrosine kinase inhibitors.

Differentiating Benign vs. Malignant Liver Masses

When an indeterminate liver mass is identified on routine abdominal imaging, distinguishing between benign lesions (such as hepatic hemangiomas, focal nodular hyperplasia, or hepatic adenomas) and malignant tumors is clinically challenging. The Serum PIVKA-II level test assists physicians in this differential diagnosis, as benign liver lesions typically do not produce PIVKA-II, whereas malignant hepatocytes demonstrate marked production and secretion of this abnormal protein.

What Does a Serum PIVKA – II Level Test Detect?

The Serum PIVKA-II level test is a highly sensitive quantitative assay that detects and measures the concentration of Des-gamma-carboxy prothrombin in the blood. Clinically, this test detects several critical physiological and pathological states:

• Hepatocellular Carcinoma (HCC): Detects the presence of malignant hepatocyte activity, even in the absence of elevated Alpha-Fetoprotein (AFP) levels.
• Early-Stage Hepatic Malignancy: Identifies subclinical neoplastic changes before they are large enough to be visualized by standard transabdominal ultrasound.
• Vitamin K Deficiency: Detects systemic depletion of Vitamin K, which is essential for the activation of clotting factors II, VII, IX, and X.
• Biliary Obstruction: Identifies impaired absorption of fat-soluble vitamins (including Vitamin K) caused by extrahepatic or intrahepatic cholestasis.
• Malabsorption Syndromes: Detects nutritional deficiencies and impaired intestinal absorption of essential fat-soluble nutrients.
• Warfarin Therapy Compliance and Effect: Reflects the therapeutic inhibition of the Vitamin K epoxide reductase enzyme by oral anticoagulants.
• Microvascular Invasion: High levels of PIVKA-II are strongly correlated with a higher risk of microscopic tumor invasion into the portal vein branches.
• Tumor Size and Burden: Detects larger tumor volumes, as PIVKA-II levels often correlate directly with the size and number of HCC nodules.
• Portal Vein Thrombosis (PVT): Assists in identifying patients at high risk of tumor-induced portal vein thrombosis due to aggressive tumor biology.
• Post-Hepatectomy Recurrence: Detects early recurrence of HCC in patients who have undergone surgical liver resection.
• Post-Transplant Recurrence: Monitors liver transplant recipients for the recurrence of primary hepatocellular carcinoma in the graft.
• Efficacy of Local Ablative Therapies: Evaluates the success of radiofrequency ablation (RFA) or microwave ablation (MWA) in destroying localized tumor tissue.
• Response to Transarterial Chemoembolization (TACE): Measures the reduction in viable tumor tissue following targeted intra-arterial chemotherapy.
• Response to Systemic Immunotherapy: Monitors the clinical efficacy of immune checkpoint inhibitors or targeted molecular therapies in advanced HCC.
• Subclinical Vitamin K Deficiency in Newborns: Detects hemorrhagic disease risk in neonates due to immature hepatic function or low Vitamin K stores.
• Liver Cirrhosis Progression: Identifies patients with stable cirrhosis who are transitioning toward active hepatocarcinogenesis.
• Drug-Induced Liver Injury (DILI): Detects severe hepatocyte dysfunction that impairs normal protein carboxylation pathways.
• Alcoholic Hepatitis Severity: Evaluates the degree of metabolic impairment in patients with acute alcoholic liver injury.
• Non-Alcoholic Steatohepatitis (NASH) Activity: Monitors high-risk NASH patients for early signs of cellular atypia and malignant transformation.
• Congenital Disorders of Glycosylation: Assists in the rare diagnostic workup of metabolic pathways affecting hepatic protein synthesis.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is committed to providing rapid, accurate, and highly reliable diagnostic reports. The Serum PIVKA-II level test is performed using advanced automated immunoassay platforms under strict quality control protocols. Typically, the turnaround time (TAT) for the Serum PIVKA-II level test is within 24 to 48 hours from the time of sample collection. This rapid reporting is crucial for clinicians who need to make timely decisions regarding oncology treatments or surgical interventions.

Patients can access their diagnostic reports conveniently through multiple digital channels provided by Chughtai Lab. Once the report is finalized and signed off by a consultant pathologist, an automated SMS notification is sent to the patient’s registered mobile number. Reports can be viewed, downloaded, and printed directly from the official Chughtai Lab website by entering the patient’s lab number and web access code. Additionally, the Chughtai Lab Mobile App offers a seamless user experience, allowing patients to maintain a digital archive of all their laboratory investigations, book home sample collection services, and share reports directly with their consulting physicians.

Serum PIVKA – II Level Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Serum PIVKA-II Concentration	< 40 mAU/mL (Reference range may vary slightly by assay)	≥ 40 mAU/mL (Elevated levels suggestive of HCC, Vitamin K deficiency, or anticoagulant use)
Alpha-Fetoprotein (AFP) Correlation	Normal AFP (< 10 ng/mL) and Normal PIVKA-II	Discordant or Concordant elevations (Both markers elevated highly increases specificity for HCC)
Vitamin K Status	Adequate systemic Vitamin K levels; normal carboxylation	Severe Vitamin K deficiency leading to elevated PIVKA-II with normal liver imaging
Anticoagulant Therapy Status	No active Vitamin K antagonist therapy	Markedly elevated PIVKA-II due to therapeutic Warfarin or Coumadin administration
Tumor Size Correlation	No hepatic mass detected; normal baseline levels	Elevated PIVKA-II (> 400 mAU/mL) often correlates with larger tumor diameter (> 3 cm)
Portal Vein Invasion Risk	Low risk; PIVKA-II within normal limits	High risk of microvascular or portal vein invasion associated with extremely high PIVKA-II levels
Post-Treatment Surveillance	Undetectable or baseline levels post-resection/ablation	Persistent elevation or rising trend indicating residual tumor or early disease recurrence

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Serum PIVKA – II Level?

• Experienced Healthcare Professionals: Chughtai Lab is staffed by highly qualified consultant pathologists, clinical chemists, and laboratory technologists who ensure the highest standards of diagnostic accuracy.
• Patient-Focused Care: The laboratory prioritizes patient comfort, safety, and convenience at every step of the diagnostic journey.
• Quality Diagnostic Services: Operating under stringent internal and external quality control programs, Chughtai Lab delivers highly reproducible and clinically valid results.
• State-of-the-Art Technology: The Serum PIVKA-II test is performed using modern, fully automated chemiluminescent immunoassay analyzers, minimizing human error.
• ISO 15189 Certification: Chughtai Lab adheres to international standards of laboratory competence, ensuring global reliability of test reports.
• Convenient Home Sample Collection: Patients who are unable to visit a center can avail of the professional home sample collection service across major cities in Pakistan.
• Seamless Digital Access: Reports are easily accessible online via the official website, SMS alerts, and the dedicated Chughtai Lab Mobile App.
• Nationwide Network: With hundreds of collection centers across Pakistan, patients can access premium diagnostic services close to their homes.